Abstract

Hereditary ovarian cancers associated with germline mutations in either BRCA1 or BRCA2 were studied to determine whether somatic mutation of the P53 gene is required for BRCA -linked ovarian tumorigenesis and further, whether the spectrum of additional somatic molecular genetic alterations present in these tumors differs from that known to exist in sporadic ovarian cancers. Forty tumors, 29 linked to BRCA1 and 11 linked to BRCA2 , were examined for mutational alterations in P53, K-RAS, ERBB-2, C-MYC , and AKT2 . The presence of a P53 mutation in 80% of these cancers indicates that P53 mutation is common but not required for BRCA -linked ovarian tumorigenesis; notably, a significantly higher proportion of the P53 mutations in BRCA2 -linked cancers were deletions or insertions compared with the more typical spectrum of missense mutations seen in BRCA1 -linked cancers. Additionally, BRCA -linked ovarian carcinomas seem to develop through a unique pathway of tumorigenesis that does not involve mutation of K-RAS or amplification of ERBB-2, C-MYC , or AKT2 . 1 Supported by Grant CA71840 from the National Cancer Institute. 2 To whom requests for reprints should be addressed, at Department of Surgery, Box 201, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.